Feb 6 (Reuters) - Bristol-Myers Squibb Co BMY.N:
Q4 ADJUSTED EPS $1.67 VERSUS IBES ESTIMATE $1.46
Q4 REVENUE $12.34 BILLION VERSUS IBES ESTIMATE $11.57 BILLION
OUTLOOK 2025 ADJUSTED EPS $6.55 TO $6.85 VERSUS IBES ESTIMATE $6.92
EXPANDS STRATEGIC PRODUCTIVITY INITIATIVE TO DELIVER ABOUT $2 BILLION IN ADDITIONAL COST SAVINGS BY2027 END
OUTLOOK 2025 REVENUES OF ABOUT $45.5 BILLION VERSUS IBES ESTIMATE $47.36 BILLION
((Reuters.Briefs@thomsonreuters.com;;))
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。